Pharma

As Covid-19 continues to disrupt traditional care norms, major pharma products have an unprecedented opportunity to define new market dynamics and demonstrate population health leadership.

Covid-19 has greatly disrupted the channels of communication between healthcare professionals and pharma manufacturers, especially those preparing for a product launch.

The world of pharma business insight is likely to change as it embraces a multi-data source reality.

Covid-19 has had a dramatic impact on where, when and how we are able to interact with our world. For hospitals, pharmacies and ‘essential’ retailers in particular, the new social distancing guidelines have made store traffic an even more crucial data metric.

Watch our on-demand webinar and listen as Ipsos’ experts review the first-wave results of our new regular COVID-19 HCP Surveillance Research of 300+ HCPs across seven specialties.

On April 1, join our presentation to glean relevant insights and the latest supporting data as Reena Sangar, Ipsos’ global head of Connected Health, presents “Exploring the physician and patient perspective on DTx: Is it in their consciousness?”

Join us for a complimentary webinar to learn how you can prepare plans addressing critical points through a proven approach to market foresight.